Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer [Phase 1]
A Phase 1 study of MGY825 in patients with advanced non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer [Phase 1]
Phase 1 trial update for ceritinib and everolimus in patients with locally advanced or metastatic solid tumors, including non-small cell lun…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer [NA]
A clinical trial is evaluating a fasting-mimicking diet in combination with immunotherapy for stage IV non-small cell lung cancer and is cur…
-
FDA approval · 2025-11-07FDA Approved: LAZCLUZE — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for LazCLUZE (lazertinib) from Janssen Biotech, Inc.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab [Phase 1, Phase 2]
Clinical trial update for ARRY-614 in combination with nivolumab or nivolumab plus ipilimumab (Phase 1/2) currently active and not recruitin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers [Phase 2]
A Phase 2 trial is evaluating Osimertinib alone or in combination with chemotherapy for EGFR-mutant metastatic non-small cell lung cancer an…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer [Phase 2]
A Phase 2 trial evaluating GEN1046 as a single agent or in combination with pembrolizumab for recurrent/metastatic non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL) [NA]
A clinical trial investigating radical radiotherapy in combination with immunotherapy for stage IV non-small cell lung cancer has completed,…
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer [Phase 1, Phase 2]
A clinical trial update on a Phase 1/2 study evaluating the combination of durvalumab, tremelimumab, and selumetinib in patients with recurr…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) [Phase 1]
Phase 1 study evaluating Boserolimab (MK-5890) alone and in combination with Pembrolizumab (MK-3475) in adults with advanced solid tumors; t…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 clinical trial update evaluating the safety and efficacy of a triple-drug combination (Zimberelimab, Domvanalimab, and Etrumadenan…
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer [Phase 2]
This document reports an update on a Phase 2 trial evaluating telisotuzumab vedotin (ABBV-399) in patients with previously treated c-Met–pos…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC [Phase 2]
This Phase 2 trial evaluated dabrafenib in combination with trametinib in Chinese patients with BRAF V600E-mutant metastatic non-small cell …
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer [Phase 1, Phase 2]
Phase I/II study evaluating VLS-1488 in adults with advanced cancer; the trial is currently recruiting across multiple solid-tumor indicatio…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 [Phase 1, Phase 2]
Phase 1/2 open-label study evaluating the safety, tolerability, PK and anti-tumor activity of YH42946 in non-small cell lung cancer and othe…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC [Phase 2]
Phase 2 study evaluating osimertinib combined with stereotactic ablative radiation (SABR) in EGFR-mutant non-small cell lung cancer.
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update for BL-M17D1 in patients with HER2-expressing or HER2-mutant advanced or metastatic solid tumors; the study is…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer [Phase 1]
A Phase 1 trial of REGN5093-M114, a METxMET antibody-drug conjugate, in MET-overexpressing advanced cancers including non-small cell lung ca…
-
CLINICAL_TRIALS research · 2025-11-03Clinical Trial Update: Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer [Phase 1]
Phase 1 clinical trial evaluating local consolidative therapy plus brigatinib in patients with stage IV or recurrent ALK-rearranged non-smal…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). [Phase 3]
A pivotal Phase 3 trial evaluated adding Tumor Treating Fields (TTFields) to radiosurgery for patients with 1-10 brain metastases from non-s…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) [Phase 2]
Phase 2 APPLE trial results evaluating osimertinib in EGFR T790M plasma-positive non-small cell lung cancer patients have been posted.
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing nivolumab alone, nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy versus platinum doublet …
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer
Clinical trial update from Mayo Clinic describes the completion of a study to develop a shared decision-making tool for patients who have ha…
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) [Phase 1, Phase 2]
Nuvalent's neladalkib (NVL-655) is being studied in a Phase 1/2 trial (ALKOVE-1) for patients with advanced non-small cell lung cancer and o…
-
EMA approval · 2025-10-29EMA Authorised: Rybrevant (amivantamab) — Janssen-Cilag International N.V.
EMA authorised Rybrevant (amivantamab) for non-small cell lung cancer. The marketing authorization holder is Janssen-Cilag International N.V…